Clinical trial
Cerebrospinal Fluid Levels of Erlotinib in Patients Receiving Erlotinib For…
NCT00305617 · The Cleveland Clinic, Other · Completed
Key facts
| NCT number | NCT00305617 |
|---|---|
| Title | Cerebrospinal Fluid Levels of Erlotinib in Patients Receiving Erlotinib For Stage III Non-Small Cell Lung Cancer |
| Official title | Evaluation of CSF Levels of Tarceva (OSI-774) in Patients With Stage III Non-Small Cell Lung Cancer and No CNS Involvement Undergoing Treatment With Tarceva |
| Lead sponsor | The Cleveland Clinic, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Other |
| Interventions | antitumor drug screening assay |
| Enrollment | 10 |
| Start date | Jan 1, 2004 |
| Primary completion | Dec 1, 2007 |
| First posted | Mar 22, 2006 |
| Last update posted | May 17, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: